6/24/2024

Bleomycin Sulfate Injection

Reason for the Shortage

- Fresenius Kabi has bleomycin injection available.
- Meitheal has bleomycin injection available.
- Pfizer has bleomycin injection available.
- Teva has bleomycin temporarily suspended with no estimated date to resume manufacturing.

Available Products

- Bleomycin sulfate lyophilized powder for solution for injection, Fresenius Kabi, 15 unit, vial, 1 count, NDC 63323-0136-10
- Bleomycin sulfate lyophilized powder for solution for injection, Fresenius Kabi, 30 unit, vial, 1 count, NDC 63323-0137-20
- Bleomycin sulfate, Hikma, 15 unit, vial, 1 count, NDC 00143-9240-01
- Bleomycin sulfate, Hikma, 30 unit, vial, 1 count, NDC 00143-9241-01
- Bleomycin sulfate, Meitheal Pharmaceuticals, 15 unit, vial, 1 count, NDC 71288-0106-10
- Bleomycin sulfate, Meitheal Pharmaceuticals, 30 unit, vial, 1 count, NDC 71288-0107-20
- Bleomycin sulfate lyophilized powder for solution for injection, Pfizer, 15 unit, vial, 1 count, NDC 61703-0332-18
- Bleomycin sulfate lyophilized powder for solution for injection, Pfizer, 30 unit, vial, 1 count, NDC 61703-0323-22

Estimated Resupply Dates

- All marketed presentations are available.

Alternative Agents & Management

- Consider evaluating the health-care system's total supply of bleomycin before beginning patients on combination chemotherapy regimens containing bleomycin. If adequate supplies are not available, select an alternative regimen.
- The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for bleomycin.
- Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
- Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
- Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.

Updated

Updated June 24, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 8, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.